A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals

Inclusion Criteria Concurrent Medication: Recommended: * Prophylaxis with isoniazid in patients not previously treated. Patients must have: * HIV seropositivity by Western blot. * Normal history and physical exam (generalized lymphadenopathy is acceptable). * Mean CD4 cell count = or \> 600 cells/mm3 for all visits (minimum 2 counts) within 60 days prior to study entry, with no single count \< 450 cells/mm3. * Negative PPD test or normal chest x-ray with positive PPD (induration = or \> 5 mm). Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Hepatitis B surface antigen positive. * Evidence of an AIDS- or ARC-defining opportunistic infection. * Evidence of disseminated tuberculosis, severe or persistent candidiasis, oral hairy leukoplakia, prolonged or very severe diarrhea, herpes zoster, or herpes simplex persisting more than one month. * Active syphilis. Patients with the following prior conditions are excluded: * Evidence of psychiatric disorder within the past year that would impair adherence to the protocol. * History of an AIDS- or ARC-defining opportunistic infection. * History of disseminated tuberculosis, severe or persistent candidiasis, oral hairy leukoplakia, prolonged or very severe diarrhea, herpes zoster, or herpes simplex persisting more than one month. Prior Medication: Excluded: * Immunomodulating agents (e.g., isoprinosine, imuthiol, lithium) within 90 days of screening. * Immunosuppressive medications within the previous 3 months. * Zidovudine (AZT) or any antiviral agent (including interferon) within the previous 6 months. * Vaccination against other pathogens within 4 weeks of initial screening laboratory work. Use of illicit drugs or significant amounts of alcohol that could significantly interfere with study compliance.